Liquid medicine composition of rosiglitazone

A technology for rosiglitazone and a composition, which is applied in the directions of drug combination, metabolic diseases, aerosol delivery, etc., can solve the problems of low solubility of rosiglitazone, single dosage form, inconvenient taking of solid preparations, etc., and achieves increased drug use Compliance and patient compliance, novel dosage forms, and beneficial effects on long-term treatment
CN102552140BActive Publication Date: 2013-05-29BEIJING HUMANWELL JUNWEI PHARM TECH CO LTD
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
BEIJING HUMANWELL JUNWEI PHARM TECH CO LTD
Publication Date
2013-05-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a liquid medicine composition of rosiglitazone or pharmaceutical salt thereof. The liquid medicine composition comprises a curing and / or preventing effective quantity of rosiglitazone or pharmaceutical salt, cosolvent, phosphate and water thereof. The composition disclosed by the invention has the advantages as shown in the specification.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention belongs to the field of pharmacy, and relates to a drug for treating hyperglycemia, in particular to a liquid composition containing rosiglitazone or its medicinal salt. The composition can be used to administer the oral mucosal route for rapid absorption and lower blood sugar. Background technique

[0002] Rosiglitazone is a thiazolidinedione, which is an effective insulin sensitizer. The chemical name of maleic acid is (Β±)-5-[[4-[2-(methyl-2-pyridylamino)ethyl [Oxy]phenyl]methyl]-2,4-thiazolidinedione (Z)-2-butenedioate, the structure is as follows:

[0003]

[0004] Rosiglitazone maleate was approved by the US FDA in May 1999. It is a potent oral treatment for type 2 (non-insulin-dependent) diabetes. It is a highly selective and powerful peroxidase. Proliferation-activated receptor gamma (PPAR gamma) agonists, which bind to and activate PPAR gamma, thereby increasing the synthesis of a variety of proteins. These proteins are involved in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More